Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PCSA with free AI briefings, catalyst countdowns, and dilution alerts.

PCSA · Processa Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$196,325 Cash on Hand
0.2mo Cash Runway
Follow PCSA by email Get an email when PCSA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PCSA, unsubscribe in one click. Privacy

📣 What PCSA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
HT-100 Duchenne Muscular Dystrophy Phase 1/2 · NCT01847573 Terminated
PCS12852 Gastroparesis Phase 2 · NCT05270460 Completed
PCS499 Necrobiosis Lipoidica Phase 2 · NCT03698864 Completed
Eniluracil (PCS6422) Breast Cancer Phase 2 · NCT06568692 Terminated
Roducitabine (RX-3117) Solid Tumor Phase 1/2 · NCT02030067 Completed
Pentoxifylline Healthy Phase 1 · NCT03836222 Completed

Also used in these trials (approved or third-party drugs, not PCSA's own candidates): Capecitabine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PCSA holds $196,325 in cash and short-term investments (as of Jun 30, 2026) and burns about $2.8M/quarter from operations, an estimated runway of 0.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PCSA files for a raise →

👥 Who Owns PCSA

Insiders 3.9% Other 5%+ holders 96.1% Institutions (16 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Chiliz Group Ltd. 5%+ holder (13D) 5,467,181 195.38% 2025-08-05
HX Entertainment Ltd 5%+ holder (13D) 305,644 10.92% 2026-02-13
CVI Investments, Inc. 5%+ holder (13G) 200,000 7.15% 2026-03-31
Mitchell P. Kopin Institution (13G, 5%+) 200,000 7.15% 2025-12-31
Soleus Capital Master Fund, L.P. Institution (13G, 5%+) 160,943 5.75% 2026-08-03
David Young
Pres. Research & Development, Director
Insider 24,412 0.87% 2026-06-30
George K Ng
Chief Executive Officer, Director · +71,568 options
Insider 21,380 0.76% 2026-08-08
Russell Skibsted
Chief Financial Officer · +30,283 options
Insider 16,689 0.60% 2026-07-26
Patrick Lin
Chief Business - Strategy Off · +19,549 options
Insider 14,853 0.53% 2026-07-26
Wendy Guy
Chief Administrative Officer · +17,669 options
Insider 14,727 0.53% 2026-07-26
Sian Bigora
Chief Development Officer
Insider 7,748 0.28% 2026-04-30
Khoso Baluch
Director · +55,998 options
Insider 2,528 0.09% 2026-07-26

Share count 2,798,241 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PCSA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PCSA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.